Research from e27, e27

Research from e27

e27 is Asia's largest Tech media platform. We cover the latest news on emerging and disruptive businesses across the region.

Private Capital Markets

<ul>
<li>Mesh Bio Co-Founders Andrew Wu and Arsen Batagov Singapore-based chronic disease management startup Mesh Bio has raised US$3.5 million in Series A financing led by East Ventures.</li>
<li>Elev8, Seed Capital, and other existing shareholders also co-invested.</li>
<li>The funding will allow Mesh Bio to offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines.</li>
</ul>


Mesh Bio Co-Founders Andrew Wu and Arsen Batagov Singapore-based chronic disease management startup Mesh Bio has raised US$3.5 million in Series A financing led by East Ventures.
Elev8, Seed Capital, and other existing shareholders also co-invested.
The funding will allow Mesh Bio to offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines.


Chronic disease management startup Mesh Bio bags US$3.5M Series A | e27

Singapore

Mesh Bio Pte Ltd designs and develops software solutions. The Company offers platform for clinical workflow automation, patient-centric visualization, and holistic assessment. Mesh Bio serves clients in Singapore.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mesh Bio (1872739D SP)

Chronic disease management startup Mesh Bio bags US$3.5M Series A | e27

Mesh Bio Co-Founders Andrew Wu and Arsen Batagov Singapore-based chronic disease management startup Mesh Bio has raised US$3.5 million in Series A...

e27

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)